Clinical trials: Retinal Disorder
Retinitis Pigmentosa, Usher Syndrome Type 2
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
PQ-421a-002 (Helia) is an open-label, extension study to evaluate the safety, tolerability and efficacy of QR 421a (ultevursen) administered via intravitreal (IVT) injection in one or both eyes, in subjects ≥ 12 years of age with…
- Trial name
- HELIA (NCT05085964)
- Testing
- RNA antisense oligonucleotide for intravitreal injection
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Laboratoires Thea
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with…
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05176717
- Testing
- QR-421a
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Laboratoires Thea
Retinopathy of Prematurity Both Eyes, Retinal Disease
Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries
This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.
- Conditions
- Retinopathy of Prematurity Both Eyes, Retinal Disease, Persistent Fetal Vasculature, Coats Disease
- Trial name
- NCT06520410
- Testing
- Pars plana vitrectomy with a 18 mm short vitrector
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Giant Cell Arteritis, Visual Impairment
Visual Involvement in Giant Cell Arteritis
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes.
- Conditions
- Giant Cell Arteritis, Visual Impairment, Central Retinal Artery Occlusion, Anterior Ischemic Optic Neuropathy
- Trial name
- Visu-GCA (NCT06500728)
- Testing
- Fluorescein and Indocyanine green Angiography, High-resolution Optical Coherence Tomography, Angio-Optical Coherence Tomography
- Where
- Italy
- Volunteers
- 762 people
- Sponsor
- ASST Fatebenefratelli Sacco
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05158296
- Testing
- Ultevursen
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 7 people
- Sponsor
- Laboratoires Thea
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Vascular Retinopathy of Left Eye (Disorder), Vascular Retinopathy of Right Eye (Disorder)
Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy
The study used a new surgical technique: intraoperative fluorescence imaging,In the 1980s, some scholars proposed the concept of intraoperative fluorescein angiography.During vitrectomy, intraoperative fluorescein angiography…
- Conditions
- Vascular Retinopathy of Left Eye (Disorder), Vascular Retinopathy of Right Eye (Disorder), Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT06343961
- Testing
- Intraoperative Fluorescein Angiography
- Volunteers
- 80 people
- Sponsor
- Jie Zhong
Macular Holes, Macular Hole of Left Eye (Disorder)
Autologous Platelet-rich Plasma as a Treatment for Macular Holes
For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect.
- Conditions
- Macular Holes, Macular Hole of Left Eye (Disorder), Macular Hole of Right Eye (Disorder)
- Trial name
- NCT06323902
- Testing
- Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation
- Where
- Colombia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Clinica Oftalmologica Paredes
Retinitis Pigmentosa
Coloured-light in Retinitis Pigmentosa.
This study will assess the effect of 2 different colours of light on colour vision in adults with retinitis pigments (RP). Participants will be 18 years or above with a genetically confirmed molecular diagnosis of RP.
- Trial name
- CLIRP (NCT06224114)
- Testing
- Coloured-light torch, Different coloured-light torch
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Cataract, Retina Disorder
A Big Data-based Cohort Study for Cataract Patients
Cataract is an important cause of blindness and visual impairment worldwide. At present, the only effective treatment method is surgery.
- Trial name
- NCT05491798
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Retinitis Pigmentosa, Inherited Retinal Dystrophy
Minocycline Treatment in Retinitis Pigmentosa
The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).
- Conditions
- Retinitis Pigmentosa, Inherited Retinal Dystrophy, Retina Disorder
- Trial name
- NCT04068207
- Testing
- Minocycline
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Diabetes, Retinal Disorders
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
The basic objective of this project is to test a modification of existing technology for monitoring the responses of the pupil to light as a method for detecting regional losses of function of the retina.
- Trial name
- NCT01546766
- Testing
- Pupillometry testing.
- Where
- 2 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Ophthalmological Disorder, Image, Body
Explainable Ocular Fundus Diseases Report Generation System
To establish a deep learning system of various ocular fundus disease analytics based on the results of multimodal examination images.
- Trial name
- NCT05622565
- Testing
- Various modalities of ocular fundus imaging
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Early Age Related Macular Degeneration (Disorder)
Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.
- Trial name
- NCT04776031
- Testing
- R:GEN Laser System
- Where
- Australia
- Volunteers
- 31 people
- Sponsor
- Lutronic Vision, Inc
Retinal Disorder
Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease
To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Leber's Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP).
- Trial name
- NCT04311112
- Testing
- ZA Low dose, ZA high dose
- Where
- United States
- Sponsor
- Retinagenix Holdings
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals